GEERT-JAN MULDER

Geert-Jan Mulder stands as a pivotal figure in the European life sciences venture capital landscape, serving as a co-founder and Managing Partner at Forbion. Forbion is renowned for its strategic investments in groundbreaking life sciences companies, and Geert-Jan's leadership has been instrumental in shaping its success and impact on global healthcare innovation.

In his role as Managing Partner, Geert-Jan Mulder is deeply involved in all aspects of Forbion's investment strategy, from identifying promising early-stage opportunities to guiding growth-stage companies towards significant milestones and successful exits. His investment focus is sharply honed on the life sciences sector, encompassing innovative biotech, pharmaceutical, and medical device companies. He seeks out ventures developing novel therapeutics, particularly in areas with high unmet medical needs, such as oncology, immunology, rare diseases, and central nervous system disorders. His approach is characterized by a blend of rigorous scientific due diligence and astute business acumen, ensuring that Forbion backs companies with strong scientific foundations and clear paths to market.

Geert-Jan's distinguished career background provides a robust foundation for his investment decisions. He holds a PhD in Molecular Biology from Leiden University and completed a postdoctoral fellowship at MIT, giving him a profound understanding of the scientific intricacies of the biotech world. Prior to co-founding Forbion in 2006, he honed his investment expertise as a partner at ABN AMRO Capital Life Sciences, where he gained extensive experience in venture capital and private equity within the healthcare sector. This unique combination of deep scientific knowledge and seasoned investment experience allows him to effectively evaluate complex scientific propositions and translate them into viable investment opportunities.

Throughout his tenure at Forbion, Geert-Jan Mulder has been involved in numerous successful investments that have brought significant value to patients and investors alike. Notable examples include his involvement with companies like Acerta Pharma, which was acquired by AstraZeneca for up to $7 billion, and Dezima Pharma, acquired by Amgen for up to $1.55 billion. These successes underscore his ability to identify and nurture companies with the potential for transformative impact. His contributions extend beyond capital, often involving active participation on company boards, providing strategic guidance, and leveraging his extensive network to accelerate growth and development. Geert-Jan Mulder continues to be a driving force behind Forbion's mission to build leading life sciences companies that deliver innovative medicines to patients worldwide.